Craft

Royalty Pharma

Stock Price

$27.1

2024-10-29

Market Capitalization

$16.2 B

2024-10-29

Revenue

$2.4 B

FY, 2025

Royalty Pharma Summary

Company Summary

Overview
Royalty Pharma is a company operating as a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. It collaborates with innovators from academic institutions, research hospitals, and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators.
Type
Public
Status
Active
Founded
1996
HQ
New York, NY, US | view all locations
Website
https://www.royaltypharma.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Pablo Legorreta

    Pablo Legorreta, Founder & Chief Executive Officer

  • Terrance Coyne

    Terrance Coyne, Chief Financial Officer

  • Molly Chiaramonte

    Molly Chiaramonte, Senior Vice President, Research & Investments

  • Marshall Urist

    Marshall Urist, Executive Vice President and Co-Head, Research & Investments

LocationsView all

1 location detected

  • New York, NY HQ

    United States

    110 E 59th St FL 33

Royalty Pharma Financials

Summary Financials

Revenue (Q1, 2026)
$630.6M
Net income (Q1, 2026)
$468.3M
Cash (Q1, 2026)
$586.4M
EBIT (Q1, 2026)
$563.0M
Enterprise value
$24.6B

Footer menu